GSK plc (FRA:GS71)

Market Cap	101.68B +41.5%
Revenue (ttm)	37.45B +4.1%
Net Income	6.55B +122.0%
EPS	1.59 +123.2%
Shares Out	n/a
PE Ratio	15.52
Forward PE	12.42
Dividend	0.76 (3.01%)
Ex-Dividend Date	Feb 19, 2026

Volume	670
Average Volume	1,453
Open	25.38
Previous Close	25.36
Day's Range	25.12 - 25.64
52-Week Range	14.68 - 26.02
Beta	n/a
RSI	66.72
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GS71

Financial Performance

In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.

Financial numbers in GBP